Nature of Operations and Basis of Presentation - Additional Information (Details) - USD ($)										3 Months Ended		6 Months Ended
	Mar. 14, 2022	Mar. 04, 2022	Jan. 14, 2022	Oct. 12, 2021	Mar. 19, 2021	Jan. 25, 2021	Apr. 30, 2020	Mar. 18, 2020	Nov. 09, 2018	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Mar. 31, 2022	Dec. 31, 2021	Oct. 04, 2021
Organization Consolidation and Presentation of Financial Statement [Line Items]
Accumulated deficit										$ 126,355,994		$ 126,355,994			$ 114,509,954
Cash and cash equivalents										$ 14,469,744		14,469,744			12,710,762
Net cash used in operating activities												(12,866,087)	$ 9,242,939
Issuance of common stock, net of issuance costs, shares										300,000
Proceeds from issuance of common stock, net of issuance costs										$ 400,000		3,524,198	$ 3,139,047
Reimbursement payment					$ 14,000,000.0
Development payments					10,000,000.0
Current liabilities										17,473,264		17,473,264			$ 29,109,950
Deferred collaboration funding										6,300,000		6,300,000
Event of Positive Safety
Organization Consolidation and Presentation of Financial Statement [Line Items]
Cash and cash equivalents										2,000,000.0		2,000,000.0
Lincoln Park
Organization Consolidation and Presentation of Financial Statement [Line Items]
Remained available under facility										$ 11,800,000		$ 11,800,000
Issuance of common stock, net of issuance costs, shares										300,000	0	300,000	200,000
Issuance of common stock, price per share										$ 1.25		$ 1.25
Proceeds from issuance of common stock, net of issuance costs												$ 400,000	$ 500,000
Proceeds from issuance of common stock gross										$ 400,000		400,000
Remaining obligation										11,800,000		11,800,000
Number of shares, company may sell on any single business day							50,000
Maximum amount of Common stock at time of sale, per regular purchase							$ 1,000,000.0
Stock to be issued value on certain limitation and condition							11,800,000
Proposed Collaboration and License Agreement
Organization Consolidation and Presentation of Financial Statement [Line Items]
Upfront non-refundable payment received					1,000,000.0
Proposed Collaboration and License Agreement | Relief Therapeutics Holding AG
Organization Consolidation and Presentation of Financial Statement [Line Items]
Upfront non-refundable payment received						$ 1,000,000.0
Proposed Collaboration and License Agreement | Secured Loan | Relief Therapeutics Holding AG
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument, term						12 months
Debt instrument, principal amount						$ 4,000,000.0
Debt instrument, interest rate						6.00%
Collaboration Agreement | Second Development Payment
Organization Consolidation and Presentation of Financial Statement [Line Items]
Deferred collaboration funding										14,200,000		14,200,000
Collaboration Agreement | Relief Therapeutics Holding AG
Organization Consolidation and Presentation of Financial Statement [Line Items]
Upfront non-refundable payment received						$ 1,000,000.0
Cash payment received					10,000,000.0						$ 10,000,000.0
Repayment of outstanding balance of prior loan and interest					4,000,000.0	4,000,000.0
Reimbursement payment					$ 14,000,000.0	$ 14,000,000.0
Potential proceeds from development payments subject to new drug application																$ 10,000,000.0
Proceeds from first tranche of development payments subject to new drug application				$ 5,000,000.0
Net profit split ratio based on territory					60.00%	60.00%
Net profit split ratio						60%:40%
Percentage of royalty net sales received					15.00%	15.00%
Milestone payment to be received					$ 6,000,000.0	$ 6,000,000.0
Collaboration Agreement | Relief Therapeutics Holding AG | First Development Payment
Organization Consolidation and Presentation of Financial Statement [Line Items]
Development payments subject new drug application											$ 10,000,000.0		$ 10,000,000.0
Collaboration Agreement | Relief Therapeutics Holding AG | Second Development Payment
Organization Consolidation and Presentation of Financial Statement [Line Items]
Potential proceeds from development payments subject to new drug application																$ 10,000,000.0
Proceeds from first tranche of development payments subject to new drug application				5,000,000.0
Collaboration Agreement | Secured Loan | Relief Therapeutics Holding AG
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument, term						12 months
Debt instrument, principal amount						$ 4,000,000.0
Debt instrument, interest rate						6.00%
Waiver and Agreement | Relief Therapeutics Holding AG
Organization Consolidation and Presentation of Financial Statement [Line Items]
Proceeds from second tranche of development payments subject to new drug application				5,000,000.0
Waiver and Agreement | Relief Therapeutics Holding AG | Second Development Payment
Organization Consolidation and Presentation of Financial Statement [Line Items]
Proceeds from first tranche of development payments subject to new drug application			$ 5,000,000.0	5,000,000.0
Proceeds from second tranche of development payments subject to new drug application				$ 5,000,000.0
SWK Credit Agreement | Bridge Loan | Lenders Party and SWK Funding LLC
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument, principal amount		$ 6,500,000
Debt instrument, interest rate, increase		3.00%
Minimum cash balance required by the loan covenants										4,000,000.0		4,000,000.0
Origination fees	$ 100,000
Warrant issued to purchase common stock		150,000
Warrant, exercise price		$ 2.46
SWK Credit Agreement | Bridge Loan | Lenders Party and SWK Funding LLC | Event of Positive Safety
Organization Consolidation and Presentation of Financial Statement [Line Items]
Cash and cash equivalents										$ 2,000,000.0		$ 2,000,000.0
SWK Credit Agreement | Bridge Loan | Lenders Party and SWK Funding LLC | If ACER-001 Approval does not Occur on or Before September 30, 2022
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument, maturity date		Mar. 04, 2024
Debt instrument repayment percentage on outstanding principal amount		150.00%
SWK Credit Agreement | Bridge Loan | Lenders Party and SWK Funding LLC | If ACER-001 Approval Occur on or Before September 30, 2022
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument repayment percentage on outstanding principal amount		130.00%
SWK Credit Agreement | Bridge Loan | Lenders Party and SWK Funding LLC | Remainder of the Time Till Bridge Loan is Outstanding
Organization Consolidation and Presentation of Financial Statement [Line Items]
Minimum cash balance required by the loan covenants														$ 6,500,000
SWK Credit Agreement | Bridge Loan | Lenders Party and SWK Funding LLC | LIBOR
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument, interest rate		1.00%
Debt instrument, description of variable rate basis												3-month LIBOR
Debt instrument, periodic payment, principal		$ 700,000
Debt instrument, frequency of periodic payment												quarterly
Debt instrument, basis spread on variable rate		11.00%
Loan repayment commencing date		Nov. 15, 2022
Secured Convertible Note Purchase Agreement | Secured Convertible Notes | MAM Aardvark, LLC and Marathon Healthcare Finance Fund, L.P.
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument, principal amount		$ 6,000,000.0
Debt instrument, interest rate		6.50%
Debt instrument, frequency of periodic payment												quarterly
Debt instrument, interest rate, increase		11.50%
Conversion price		$ 2.50
Marathon Credit Agreement | Term Loan | Lender Party and Marathon
Organization Consolidation and Presentation of Financial Statement [Line Items]
Debt instrument, principal amount		$ 42,500,000
Debt instrument, interest rate		13.50%
Debt instrument, frequency of periodic payment												quarterly
Debt instrument, maturity date		Dec. 31, 2028
Percentage of commitment fee		1.50%
Line of credit facility, maximum borrowing capacity		$ 92,500,000
Line of credit facility, additional borrowing capacity		$ 50,000,000.0
Percentage of option to capitalize	4.00%
Debt instrument amortization percentage		2.78%
Debt instrument, maturity date, description												The final maturity date of the Term Loan would be the earlier of six years after the Term Loan Funding Date or December 31, 2028.
Percentage of prepayment, prior to March 4, 2025		5.00%
Percentage of prepayment, on or after March 4, 2025, but prior to March 4, 2026		3.00%
Percentage of prepayment, on or after March 4, 2026, but prior to March 4, 2027		2.00%
Percentage of prepayment, on or after March 4, 2027		1.00%
Payment for commitment fees		$ 200,000
Payment for additional commitment fees		$ 600,000
Percentage of aggregate revenue as royalty payments		2.00%
Royalty payments on aggregate revenue cap amount		$ 15,000,000.0
Weighted Average | Lincoln Park
Organization Consolidation and Presentation of Financial Statement [Line Items]
Issuance of common stock, price per share										$ 1.25	$ 2.47	$ 1.25	$ 2.47
Minimum [Member] | SWK Credit Agreement | Bridge Loan | Lenders Party and SWK Funding LLC
Organization Consolidation and Presentation of Financial Statement [Line Items]
Number of days required for cash balance												20 days
Minimum [Member] | SWK Credit Agreement | Bridge Loan | Lenders Party and SWK Funding LLC | Remainder of the Time Till Bridge Loan is Outstanding
Organization Consolidation and Presentation of Financial Statement [Line Items]
Number of days required for cash balance												40 days
Maximum | Lincoln Park
Organization Consolidation and Presentation of Financial Statement [Line Items]
Shares value might be issued under agreement							$ 15,000,000.0
Number of shares, company may sell on any single business day							100,000
Maximum | Collaboration Agreement | Relief Therapeutics Holding AG
Organization Consolidation and Presentation of Financial Statement [Line Items]
Development payments					$ 20,000,000.0
At-the-Market Facility
Organization Consolidation and Presentation of Financial Statement [Line Items]
Remained available under facility										$ 36,700,000		$ 36,700,000
Common stock offering costs										$ 200,000		$ 200,000	$ 200,000
Issuance of common stock, net of issuance costs, shares										1,062,547		1,062,547	877,107
Proceeds from issuance of common stock, net of issuance costs										$ 3,100,000		$ 3,100,000	$ 2,600,000
Proceeds from issuance of common stock gross										$ 3,300,000		$ 3,300,000	$ 2,800,000
At-the-Market Facility | Weighted Average
Organization Consolidation and Presentation of Financial Statement [Line Items]
Issuance of common stock, price per share										$ 3.0719	$ 3.1692	$ 3.0719	$ 3.1692
At-the-Market Facility | Maximum
Organization Consolidation and Presentation of Financial Statement [Line Items]
Aggregate offering price of common stock								$ 50,000,000.0	$ 50,000,000.0